Forty Seven Inc. to Present at the 2018 BIO CEO & Investor Conference
MENLO PARK, February 6, 2018 – Forty Seven Inc., a clinical-stage company focused on developing the next generation of transformational immuno-oncology treatments to enable patient’s immune systems to defeat their cancer, today announced that Forty Seven’s President and Chief Executive Officer, Mark McCamish, M.D., Ph.D., will present a company overview at the 2018 BIO CEO & Investor Conference on Tuesday, February 13 at 2:15 p.m. ET in New York, NY.
About Forty Seven Inc.:
Forty Seven Inc. is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in five clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin’s lymphoma and colorectal carcinoma.
For more information please visit www.fortyseveninc.com or contact firstname.lastname@example.org.
For journalist enquiries please contact Ryan Ferrell at email@example.com or phone (312) 506-5202.
For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at firstname.lastname@example.org or phone (212) 362-1200.